CONMED at Wells Fargo conference: growth story gains momentum

CONMED reiterated 2026 revenue growth guidance of 5%-6%, implying acceleration to 6%-8% in the second half, after delivering 6% organic constant-currency growth in Q2. Management expects 50-100bps of gross-margin expansion and improved free-cash-flow conversion through inventory and working-capital actions, supported by AirSeal, BioBrace, Buffalo Filter and international operations, which represent 45% of sales. The company continues share repurchases and sees tuck-in M&A potential of roughly $10 million to more than $200 million, although deleveraging and managing higher interest expense remain priorities.

Analysis

CNMD’s investable inflection is not the stated growth range but the potential for a mix-driven rerating: higher-disposable utilization from AirSeal and incremental international launches can raise gross profit faster than reported revenue. The key is whether commercial investment converts into recurring procedure pull-through rather than merely capital placements; sustained high-single-/low-double-digit growth in AirSeal dollars would support a credible 2027 organic-growth step-up and reduce the market’s historical “mid-single-digit medtech” discount.

The underappreciated competitive beneficiary is CNMD’s vendor-neutral position as robotic surgery fragments beyond ISRG. New robotic platforms need validated accessory ecosystems, and CNMD can participate without bearing robot-development capital intensity. Conversely, ISRG’s closed-system economics create the principal risk: if integrated insufflation attachment and contracting improve, CNMD’s addressable procedure share could compress even while robotics volumes grow. The cited clinical study is directionally useful but too small to establish broad formulary conversion; hospital purchasing and disposable attach-rate data matter more than promotional claims.

Near term, the setup is constructive only if second-half acceleration appears in reported organic growth and working-capital release rather than through FX, tariff items, or inventory drawdown. Over 6-18 months, reduced leverage and refinancing could turn interest expense from an EPS headwind into upside, but management’s simultaneous buyback, R&D, sales-force expansion, and M&A ambitions create capital-allocation tension. A higher-rate environment or a revenue miss would expose this tension quickly because small-cap medtech multiples are sensitive to both growth durability and balance-sheet optionality.

Contrarian view: the market may already price much of the operational narrative after management’s repeated emphasis on acceleration. The more asymmetric outcome is a modest growth beat paired with FCF conversion improvement, which could enable debt reduction and tuck-in capacity without sacrificing investment; that combination is more rerating-relevant than a standalone 50-100 bp gross-margin gain.

Key Decisions for Investors

• Initiate a starter long CNMD only ahead of the next earnings print if shares remain below the level implied by a peer-average mid-cap medtech multiple; add on evidence that AirSeal disposable revenue and total organic growth both accelerate sequentially. Target a 15-25% upside over 6-12 months from growth/multiple expansion; exit if organic growth falls below 5% or AirSeal fails to sustain sequential acceleration.
• Express the robotics-accessory thesis as long CNMD / short a diversified medtech ETF such as IHI, sized beta-neutral, over 6-12 months. This isolates CNMD’s potential share and operating-leverage inflection from procedure-volume and rate-driven sector moves; cover if CNMD’s gross-margin expansion stalls or leverage rises despite claimed FCF improvement.
• Do not short ISRG on this development. Instead, monitor ISRG disclosures on integrated insufflation adoption, accessory contracting, and procedure attach rates; a material increase in closed-system utilization would be the clearest falsifier of CNMD’s vendor-neutral robotics upside.
• Set an alert for refinancing or debt-reduction milestones over the next 1-3 quarters. A lower interest-expense run rate plus stable buybacks would justify increasing CNMD exposure; an acquisition before demonstrable deleveraging is a governance/capital-allocation warning and reason to reduce.